Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Gonzalez

Neurology Bay Harbor Islands, FL Medical Doctor

NPI 1619029287 CMS profile 27992

1111 Kane Concourse Ste 504, Bay Harbor Islands, FL 33154

Open in the dashboard

General payments

$5,889

282 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Gonzalez of Bay Harbor Islands, FL is reported in the CMS Open Payments database as having received $5,889 across 282 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,651 76
2024 General $1,220 60
2023 General $1,240 56
2022 General $577 33
2021 General $999 46
2020 General $141 8
2019 General $62 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Gonzalez
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to George Gonzalez were reported at $1,651. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year George Gonzalez Neurology median Middle half National median
2019 $62 $474 $118–$2,177 $163
2020 $141 $367 $82–$2,309 $114
2021 $999 $438 $104–$2,547 $132
2022 $577 $442 $103–$2,388 $149
2023 $1,240 $464 $119–$2,312 $160
2024 $1,220 $468 $119–$2,323 $164
2025 $1,651 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,577 83 payments
  2. Biogen, Inc. $481 24 payments
  3. Ge Healthcare $457 21 payments
  4. Pfizer Inc. $410 20 payments
  5. Eisai Inc. $284 11 payments
  6. Alexion Pharmaceuticals, Inc. $270 13 payments
  7. Argenx US, Inc. $249 9 payments
  8. Impel Pharmaceuticals Inc. $190 11 payments
  9. Biohaven Pharmaceuticals, Inc. $168 10 payments
  10. Teva Pharmaceuticals USA, Inc. $163 8 payments
  11. Other $1,639 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,889 282 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $995 52 payments
  2. QULIPTA $856 49 payments
  3. NURTEC ODT Primary Care $318 21 payments
  4. NURTEC ODT Pain $315 16 payments
  5. ZAVZPRET $299 15 payments
  6. Leqembi $264 10 payments
  7. BOTOX $250 12 payments
  8. VYVGART Hytrulo $195 7 payments
  9. ULTOMIRIS $181 9 payments
  10. TYSABRI $174 7 payments
  11. Other $2,547 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

889

Median for Neurology: 833

Drug cost

$32,590

Median for Neurology: $202,670

Branded share of claims

36.6%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Memantine Hcl Er Memantine Hcl Brand 79 $7,295
Lacosamide Generic 20 $3,498
Pyridostigmine Bromide Generic 18 $3,054
Carbidopa-Levodopa Carbidopa/Levodopa Brand 163 $2,709
Levetiracetam Generic 74 $2,395
Gabapentin Generic 62 $1,845
Divalproex Sodium Er Divalproex Sodium Brand 29 $1,685
Carbamazepine Er Carbamazepine Brand 11 $1,657
Amitriptyline Hcl Generic 64 $1,512
Donepezil Hcl Generic 93 $1,043

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$142,751

Medicare's payments for the services billed

Medicare patients

439

Average age 78

Services billed

1,992

220 women, 219 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 47%
Depression 38%
Diabetes 37%
Chronic kidney disease 32%
Atrial fibrillation 31%
Heart failure 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$241 — —
UBRELVY
$158 — —
Leqembi
$115 — —
Apokyn
$72 — —
RYTARY
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

282 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record